News

For trichotillomania, try behavioral therapy before drugs


 

EXPERT ANALYSIS FROM THE PSYCHOPHARMACOLOGY UPDATE INSTITUTE

Dr. Coffey disclosed that she is on the advisory boards of Eli Lilly, Jazz Pharmaceuticals, and Novartis. She has received research support from Boehringer Ingelheim, Bristol-Myers Squibb, CatalystPharma, Eli Lilly, Otsuka Pharmaceutical, and Shire. She is on the speakers bureau for Quintiles.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Oseltamivir suspension back in production
MDedge Family Medicine
Premature infants on parenteral nutrition among the casualties in zinc shortage
MDedge Family Medicine
Perception of safety spurs e-cigarette use in young adults
MDedge Family Medicine
FDA clears assay to help diagnose developmental delay, intellectual disabilities
MDedge Family Medicine
Substantial drop in rate of NICU candidiasis
MDedge Family Medicine
Excessive GBS sepsis evaluations of neonates curbed
MDedge Family Medicine
When ADHD doesn’t improve, check medication adherence first
MDedge Family Medicine
Environmental stressors play major role in pediatric migraines
MDedge Family Medicine
Drug therapy for children with autism: No magic bullets yet
MDedge Family Medicine
Caffeine-laden drinks emit ‘absolute safety signals’ for teens
MDedge Family Medicine